Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Scott

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Item reduction and psychometric validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS)Robert Arbuckle, Marci Clark, Jane Harness, et al.
BMC Infectious Diseases|August 29, 2014
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infectionJane Scott, Kathleen Rosa, Min Fu, et al.
Carbohydrate Polymers|January 14, 2023
Biofilm inspired fabrication of functional bacterial cellulose through ex-situ and in-situ approachesKatie A Gilmour, Mahab Aljannat, Christopher Markwell, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 19, 2010
Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibioticsMatteo Fallani, David Young, Jane Scott, et al.
Influenza and Other Respiratory Viruses|September 2, 2021
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact QuestionnaireAnn R Falsey, Edward E Walsh, Richard H Osborne, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 22, 2014
Gender-specific research for emergency diagnosis and management of ischemic heart disease: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research WorkgroupBasmah Safdar, John T Nagurney, Ayodola Anise, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 19, 2012
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standardsMichael Brundage, Jane Blazeby, Dennis Revicki, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Item reduction and psychometric validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS)Robert Arbuckle, Marci Clark, Jane Harness, et al.
BMC Infectious Diseases|August 29, 2014
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infectionJane Scott, Kathleen Rosa, Min Fu, et al.
Carbohydrate Polymers|January 14, 2023
Biofilm inspired fabrication of functional bacterial cellulose through ex-situ and in-situ approachesKatie A Gilmour, Mahab Aljannat, Christopher Markwell, et al.
Journal of Pediatric Gastroenterology and Nutrition|May 19, 2010
Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibioticsMatteo Fallani, David Young, Jane Scott, et al.
Influenza and Other Respiratory Viruses|September 2, 2021
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact QuestionnaireAnn R Falsey, Edward E Walsh, Richard H Osborne, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 22, 2014
Gender-specific research for emergency diagnosis and management of ischemic heart disease: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research WorkgroupBasmah Safdar, John T Nagurney, Ayodola Anise, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 19, 2012
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standardsMichael Brundage, Jane Blazeby, Dennis Revicki, et al.
Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Pageof 8